Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom.…
Genflow Biosciences Reports Positive Gene Therapy Results In Older Dogs
Genflow Biosciences (LON: GENF) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 1.550 GBp on 20 November 2026, down 13.9% over 52 weeks. Its 52-week range is 1.211 GBp to 3.120 GBp: the price is 50.3% below the high and 28.0% above the low.
Its market capitalisation is 9.22M GBP.
Genflow Biosciences reports return on equity of 257.4% and an operating margin of -187.8%.
It holds more cash than debt, a net cash position of 632.55K GBP. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.